{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T09:13:57Z","timestamp":1725527637871},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,10,3]],"date-time":"2013-10-03T00:00:00Z","timestamp":1380758400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1186\/1471-244x-13-243","type":"journal-article","created":{"date-parts":[[2013,10,3]],"date-time":"2013-10-03T09:07:50Z","timestamp":1380791270000},"source":"Crossref","is-referenced-by-count":2,"title":["Japan useful medication program for schizophrenia (JUMPs)-long-term study on discontinuation rate, resolution and remission, and improvement in social functioning rate associated with atypical antipsychotic medications in patients with schizophrenia"],"prefix":"10.1186","volume":"13","author":[{"given":"Jun","family":"Ishigooka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuyuki","family":"Nakagome","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuro","family":"Ohmori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nakao","family":"Iwata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,10,3]]},"reference":[{"key":"1429_CR1","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1080\/09540260701563320","volume":"19","author":"C Depp","year":"2007","unstructured":"Depp C, Lebowitz BD: Clinical trials: bridging the gap between efficacy and effectiveness. Int Rev Psychiatry. 2007, 19: 531-539. 10.1080\/09540260701563320.","journal-title":"Int Rev Psychiatry"},{"key":"1429_CR2","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1056\/NEJMoa051688","volume":"353","author":"JA Lieberman","year":"2005","unstructured":"Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, et al: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005, 353: 1209-1223. 10.1056\/NEJMoa051688.","journal-title":"N Engl J Med"},{"key":"1429_CR3","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.schres.2008.11.007","volume":"108","author":"D Novick","year":"2009","unstructured":"Novick D, Haro JM, Suarez D, Vieta E, et al: Recovery in the outpatient setting: 36-month results from the Schizophrenia Outpatients Health Outcomes (SOHO) study. Schizophr Res. 2009, 108: 223-230. 10.1016\/j.schres.2008.11.007.","journal-title":"Schizophr Res"},{"key":"1429_CR4","volume-title":"MacArthur Competence Assessment Tool for Clinical Research (MacCAT-CR)","author":"PS Appelbaum","year":"2001","unstructured":"Appelbaum PS, Grisso T: MacArthur Competence Assessment Tool for Clinical Research (MacCAT-CR). 2001, Sarasota, FL: Professional Resource Press"},{"key":"1429_CR5","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1176\/appi.ajp.162.3.441","volume":"162","author":"NC Andreasen","year":"2005","unstructured":"Andreasen NC, Carpenter WT, Kane JM, Lasser RA, et al: Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry. 2005, 162: 441-449. 10.1176\/appi.ajp.162.3.441.","journal-title":"Am J Psychiatry"},{"key":"1429_CR6","volume-title":"DIEPSS: A second-generation rating scale for antipsychotic-induced extrapyramidal symptoms: Drug-induced Extrapyramidal Symptoms Scale","author":"T Inada","year":"2009","unstructured":"Inada T: DIEPSS: A second-generation rating scale for antipsychotic-induced extrapyramidal symptoms: Drug-induced Extrapyramidal Symptoms Scale. 2009, Tokyo, Japan: Seiwa Shoten Publishers, Inc."},{"key":"1429_CR7","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1001\/archpsyc.63.10.1079","volume":"63","author":"PB Jones","year":"2006","unstructured":"Jones PB, Barnes TR, Davies L, Dunn G, et al: Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry. 2006, 63: 1079-1087. 10.1001\/archpsyc.63.10.1079.","journal-title":"Arch Gen Psychiatry"},{"key":"1429_CR8","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1176\/ajp.2006.163.4.600","volume":"163","author":"JP McEvoy","year":"2006","unstructured":"McEvoy JP, Lieberman JA, Stroup TS, et al: Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry. 2006, 163: 600-610. 10.1176\/appi.ajp.163.4.600.","journal-title":"Am J Psychiatry"},{"key":"1429_CR9","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/S0140-6736(08)60486-9","volume":"371","author":"RS Kahn","year":"2008","unstructured":"Kahn RS, Fleischhacker WW, Boter H, Davidson M, et al: Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet. 2008, 371: 1085-1097. 10.1016\/S0140-6736(08)60486-9.","journal-title":"Lancet"},{"key":"1429_CR10","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1124\/jpet.102.033175","volume":"302","author":"KD Burris","year":"2002","unstructured":"Burris KD, Molski TF, Xu C, Ryan E, et al: Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther. 2002, 302: 381-389. 10.1124\/jpet.102.033175.","journal-title":"J Pharmacol Exp Ther"},{"issue":"Suppl","key":"1429_CR11","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.clinthera.2010.01.021","volume":"32","author":"E Stip","year":"2010","unstructured":"Stip E, Tourjman V: Aripiprazole in schizophrenia and schizoaffectivedisorder: a review. Clin Ther. 2010, 32 (Suppl): 3-20.","journal-title":"Clin Ther"},{"key":"1429_CR12","doi-asserted-by":"publisher","first-page":"65","DOI":"10.2165\/11202620-000000000-00000","volume":"24","author":"ED Deeks","year":"2010","unstructured":"Deeks ED, Keating GM: Blonanserin: a review of its use in the management of schizophrenia. CNS Drugs. 2010, 24: 65-84. 10.2165\/11202620-000000000-00000.","journal-title":"CNS Drugs"},{"key":"1429_CR13","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/sj.mp.4002062","volume":"12","author":"JA Gray","year":"2007","unstructured":"Gray JA, Roth BL: The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007, 12: 904-922. 10.1038\/sj.mp.4002062.","journal-title":"Mol Psychiatry"},{"key":"1429_CR14","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1185\/030079906X132613","volume":"22","author":"R Conley","year":"2006","unstructured":"Conley R, Gupta SK, Sathyan G: Clinical spectrum of the osmotic-controlled release oral delivery system (OROS), an advanced oral delivery form. Curr Med Res Opin. 2006, 22: 1879-1892. 10.1185\/030079906X132613.","journal-title":"Curr Med Res Opin"},{"key":"1429_CR15","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.2165\/11204840-000000000-00000","volume":"70","author":"CM Chwieduk","year":"2010","unstructured":"Chwieduk CM, Keating GM: Paliperidone extended release: a review of its use in the management of schizophrenia. Drugs. 2010, 70: 1295-1317. 10.2165\/11204840-000000000-00000.","journal-title":"Drugs"},{"key":"1429_CR16","doi-asserted-by":"publisher","first-page":"606","DOI":"10.5414\/CPP47606","volume":"47","author":"S Boom","year":"2009","unstructured":"Boom S, Thyssen A, Crauwels H, Molz KH, et al: The influence of hepatic impairment on the pharmacokinetics of paliperidone. Int J Clin Pharmacol Ther. 2009, 47: 606-616. 10.5414\/CPP47606.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"1429_CR17","doi-asserted-by":"publisher","first-page":"763","DOI":"10.4088\/JCP.v63n0903","volume":"63","author":"JM Kane","year":"2002","unstructured":"Kane JM, Carson WH, Saha AR, McQuade RD, et al: Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry. 2002, 63: 763-771. 10.4088\/JCP.v63n0903.","journal-title":"J Clin Psychiatry"},{"key":"1429_CR18","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1001\/archpsyc.60.7.681","volume":"60","author":"SG Potkin","year":"2003","unstructured":"Potkin SG, Saha AR, Kujawa MJ, Carson WH, et al: Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry. 2003, 60: 681-690. 10.1001\/archpsyc.60.7.681.","journal-title":"Arch Gen Psychiatry"},{"key":"1429_CR19","doi-asserted-by":"publisher","first-page":"615","DOI":"10.2165\/00023210-200923070-00006","volume":"23","author":"E Garcia","year":"2009","unstructured":"Garcia E, Robert M, Peris F, Nakamura H, et al: The efficacy and safety of blonanserin compared with haloperidol in acute-phase schizophrenia: a randomized, double-blind, placebo-controlled, multicentre study. CNS Drugs. 2009, 23: 615-625. 10.2165\/00023210-200923070-00006.","journal-title":"CNS Drugs"},{"key":"1429_CR20","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1097\/WNF.0b013e3181dcda50","volume":"33","author":"J Yang","year":"2010","unstructured":"Yang J, Bahk WM, Cho HS, Jeon YW, et al: Efficacy and tolerability of Blonanserin in the patients with schizophrenia: a randomized, double-blind, risperidone-compared trial. Clin Neuropharmacol. 2010, 33: 169-175. 10.1097\/WNF.0b013e3181dcda50.","journal-title":"Clin Neuropharmacol"},{"key":"1429_CR21","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.schres.2007.03.003","volume":"93","author":"M Davidson","year":"2007","unstructured":"Davidson M, Emsley R, Kramer M, Ford L, et al: Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study. Schizophr Res. 2007, 93: 117-130. 10.1016\/j.schres.2007.03.003.","journal-title":"Schizophr Res"},{"key":"1429_CR22","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.schres.2006.09.012","volume":"90","author":"J Kane","year":"2007","unstructured":"Kane J, Canas F, Kramer M, Ford L, et al: Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial. Schizophr Res. 2007, 90: 147-161. 10.1016\/j.schres.2006.09.012.","journal-title":"Schizophr Res"},{"key":"1429_CR23","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1016\/j.clinthera.2006.11.007","volume":"28","author":"RS McIntyre","year":"2006","unstructured":"McIntyre RS, Fallu A, Konarski JZ: Measurable outcomes in psychiatric disorders: remission as a marker of wellness. Clin Ther. 2006, 28: 1882-1891. 10.1016\/j.clinthera.2006.11.007.","journal-title":"Clin Ther"},{"issue":"Suppl 2","key":"1429_CR24","doi-asserted-by":"publisher","first-page":"S115","DOI":"10.1016\/j.euroneuro.2007.02.003","volume":"17","author":"P Thomas","year":"2007","unstructured":"Thomas P: The stable patient with schizophrenia\u2013from antipsychotic effectiveness to adherence. Eur Neuropsychopharmacol. 2007, 17 (Suppl 2): S115-S122.","journal-title":"Eur Neuropsychopharmacol"},{"key":"1429_CR25","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.schres.2010.02.1073","volume":"119","author":"JF Gleeson","year":"2010","unstructured":"Gleeson JF, Alvarez-Jimenez M, Cotton SM, et al: A systematic review of relapse measurement in randomized controlled trials of relapse prevention in first-episode psychosis. Schizophr Res. 2010, 119: 79-88. 10.1016\/j.schres.2010.02.1073.","journal-title":"Schizophr Res"},{"key":"1429_CR26","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1176\/appi.ajp.2011.10060908","volume":"168","author":"SM Essock","year":"2011","unstructured":"Essock SM, Schooler NR, Stroup TS, McEvoy JP, et al: Effectiveness of switching from antipsychotic polypharmacy to monotherapy. Am J Psychiatry. 2011, 168: 702-708. 10.1176\/appi.ajp.2011.10060908.","journal-title":"Am J Psychiatry"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-244X-13-243.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-244X-13-243\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-244X-13-243","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2016,7,13]],"date-time":"2016-07-13T01:25:13Z","timestamp":1468373113000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/1471-244X-13-243"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,3]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["1429"],"URL":"https:\/\/doi.org\/10.1186\/1471-244x-13-243","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10,3]]},"article-number":"243"}}